The North American OTC pharmaceuticals market grew with CAGRs of 4.2% from 2005-2009, to reach a value of $38.6 billion in 2009. Cough and cold preparations sales proved the most lucrative for the global OTC pharmaceuticals market, generating total revenues of $19.5 billion, equivalent to 17.6% of the market's overall value.
This research report provides an analysis of the U.S. OTC Pharmaceutical market through 2014. It provides and analysis of this high-growth industry in terms of market value, market segmentation, competitive landscape and the major players.
The United States has a large market for OTC pharmaceuticals, and it is regulated by the Food and Drug Administration
(FDA
). While the laws governing OTC pharmaceuticals are very strict, the market itself has grown over the years and has many major players operating in the industry.
With market growth mitigating rivalry in the market, manufacturers are focusing on product differentiation in order to make a niche for themselves.
With the global OTC pharmaceuticals industry expected to grow at a moderate pace in the coming years, the U.S. OTC pharmaceuticals market is also looking for a decelerated growth till the year 2014. The industry is expected to have a market value of $31.9 billion by the end of 2014.
Major pharmaceutical companies are profiled including SWOT analysis for:
Bayer AG
Bristol-Myers Squibb Company
Novartis AG
Pfizer Inc
Sanofi-Aventis SA
Johnson & Johnson
GlaxoSmithKline Plc
GelStat Corporation
Key Topics Covered:
Analysis of the Global and U.S. OTC Pharmaceuticals Market including
Industry Segmentation
Global Market Share
Competitive Landscape
Institutional Framework for OTC Drugs in the U.S.
U.S. OTC Drug Monograph
Tables Included:
Average Drug Prices in the U.S.
Cost of 30-day Claritin Treatment
Common OTC Drug Label
Microencapsulation by Phase Separation
Diffucaps® Technology
AdvaTab® ODT Technology
This comprehensive profile of the U.S. OTC Pharmaceutical is a required resource for pharma executives, investors, and R&D firms.
View Table of ContentsPages: 78
Publication Date: December 2011
Publisher: Pharma-Reports
)